The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(5-(4-(Allyloxy)-3-methoxyphenyl)-2-amino-5,8-dihydro-3H,6H-pyrido[2,3-d]pyrimidine-4,7-dione ID: ALA5208587
Cas Number: 878437-15-1
PubChem CID: 135511602
Product Number: P286844, Order Now?
Max Phase: Preclinical
Molecular Formula: C17H18N4O4
Molecular Weight: 342.36
Associated Items:
Names and Identifiers Canonical SMILES: C=CCOc1ccc(C2CC(=O)Nc3nc(N)[nH]c(=O)c32)cc1OC
Standard InChI: InChI=1S/C17H18N4O4/c1-3-6-25-11-5-4-9(7-12(11)24-2)10-8-13(22)19-15-14(10)16(23)21-17(18)20-15/h3-5,7,10H,1,6,8H2,2H3,(H4,18,19,20,21,22,23)
Standard InChI Key: DCSWTWUTSKSXOV-UHFFFAOYSA-N
Molfile:
RDKit 2D
25 27 0 0 0 0 0 0 0 0999 V2000
0.3561 -2.0607 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3583 -1.6481 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0727 -2.0607 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0727 -2.8857 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3583 -3.2982 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.3561 -2.8857 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3583 -0.8234 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3558 -0.4108 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3550 0.4114 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3593 0.8239 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0708 0.4149 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0756 -0.4092 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.0706 -3.2982 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.7851 -2.8856 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7851 -2.0606 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.0706 -1.6481 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.0706 -0.8234 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-1.7870 -3.2980 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2.4993 -3.2980 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.3593 1.6486 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-1.0736 2.0610 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0736 2.8858 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.7879 3.2982 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.7851 0.8273 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-2.4993 0.4149 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
3 2 1 0
4 3 1 0
5 4 1 0
1 6 2 0
6 5 1 0
7 2 1 0
8 7 2 0
9 8 1 0
10 9 2 0
11 10 1 0
7 12 1 0
12 11 2 0
6 13 1 0
14 13 2 0
15 14 1 0
16 15 1 0
1 16 1 0
16 17 2 0
4 18 2 0
14 19 1 0
10 20 1 0
20 21 1 0
21 22 1 0
22 23 2 0
11 24 1 0
24 25 1 0
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 342.36Molecular Weight (Monoisotopic): 342.1328AlogP: 1.40#Rotatable Bonds: 5Polar Surface Area: 119.33Molecular Species: NEUTRALHBA: 6HBD: 3#RO5 Violations: ┄HBA (Lipinski): 8HBD (Lipinski): 4#RO5 Violations (Lipinski): ┄CX Acidic pKa: 7.98CX Basic pKa: 1.99CX LogP: 0.56CX LogD: 0.47Aromatic Rings: 2Heavy Atoms: 25QED Weighted: 0.71Np Likeness Score: -0.20
References 1. Takasaki I, Watanabe A, Okada T, Kanayama D, Nagashima R, Shudo M, Shimodaira A, Nunomura K, Lin B, Watanabe Y, Gouda H, Miyata A, Kurihara T, Toyooka N.. (2022) Design and synthesis of pyrido[2,3-d]pyrimidine derivatives for a novel PAC1 receptor antagonist., 231 [PMID:35124531 ] [10.1016/j.ejmech.2022.114160 ]